Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
42
ENTA Quote, Financials, Valuation and Earnings
Last price:
$16.45
Seasonality move
:
10.84%
Day range:
$15.84 - $17.05
52-week range:
$4.09 - $17.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.42x
P/B ratio:
7.40x
Volume:
292.1K
Avg. volume:
360K
1-year change:
172.13%
Market cap:
$479.1M
Revenue:
$65.3M
EPS (TTM):
-$3.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENTA
Enanta Pharmaceuticals, Inc.
|
$16M | -$1.01 | -4.83% | -23.06% | $19.13 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENTA
Enanta Pharmaceuticals, Inc.
|
$16.60 | $19.13 | $479.1M | -- | $0.00 | 0% | 5.42x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENTA
Enanta Pharmaceuticals, Inc.
|
75.65% | 2.579 | 78.54% | 4.03x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENTA
Enanta Pharmaceuticals, Inc.
|
$13.8M | -$18.4M | -26.42% | -85.63% | -121.56% | -$7.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Enanta Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ENTA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of -255.85%. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ENTAEnanta Pharmaceuticals, Inc.91.51% -$0.87 $265.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ENTA or NBY?
Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 15.21%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Enanta Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Enanta Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENTAEnanta Pharmaceuticals, Inc.5 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ENTA or NBY More Risky?
Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ENTA or NBY?
Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTA or NBY?
Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 5.42x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTAEnanta Pharmaceuticals, Inc.5.42x -- $15.1M -$18.7M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns ENTA or NNVC?
NanoViricides, Inc. has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ENTAEnanta Pharmaceuticals, Inc.91.51% -$0.87 $265.8M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ENTA or NNVC?
Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 15.21%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that NanoViricides, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than Enanta Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENTAEnanta Pharmaceuticals, Inc.5 1 0 NNVCNanoViricides, Inc.1 0 0 -
Is ENTA or NNVC More Risky?
Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock ENTA or NNVC?
Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTA or NNVC?
Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than NanoViricides, Inc. quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 5.42x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTAEnanta Pharmaceuticals, Inc.5.42x -- $15.1M -$18.7M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ENTA or OGEN?
Oragenics, Inc. has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ENTAEnanta Pharmaceuticals, Inc.91.51% -$0.87 $265.8M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ENTA or OGEN?
Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 15.21%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Oragenics, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than Enanta Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENTAEnanta Pharmaceuticals, Inc.5 1 0 OGENOragenics, Inc.1 0 0 -
Is ENTA or OGEN More Risky?
Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ENTA or OGEN?
Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTA or OGEN?
Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than Oragenics, Inc. quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 5.42x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTAEnanta Pharmaceuticals, Inc.5.42x -- $15.1M -$18.7M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ENTA or PTN?
Palatin Technologies has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENTAEnanta Pharmaceuticals, Inc.91.51% -$0.87 $265.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ENTA or PTN?
Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 15.21%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Enanta Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENTAEnanta Pharmaceuticals, Inc.5 1 0 PTNPalatin Technologies0 0 0 -
Is ENTA or PTN More Risky?
Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ENTA or PTN?
Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTA or PTN?
Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than Palatin Technologies quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is higher than Palatin Technologies's net income of --. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 5.42x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTAEnanta Pharmaceuticals, Inc.5.42x -- $15.1M -$18.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ENTA or TOVX?
Theriva Biologics, Inc. has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ENTAEnanta Pharmaceuticals, Inc.91.51% -$0.87 $265.8M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ENTA or TOVX?
Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 15.21%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Enanta Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENTAEnanta Pharmaceuticals, Inc.5 1 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ENTA or TOVX More Risky?
Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ENTA or TOVX?
Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTA or TOVX?
Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 5.42x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTAEnanta Pharmaceuticals, Inc.5.42x -- $15.1M -$18.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.39% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 2.27% over the past day.
Buy
66
ASTS alert for Dec 26
AST Spacemobile, Inc. [ASTS] is down 6.84% over the past day.
